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osting by EAbstract Background: Primary angioplasty decreases mortality and improves long-term out-
comes for patients with STEMI. To be most effective, it needs to be performed expediently, with
door-to-balloon times (D2B) less than 90 min.
Methods: From January 2005 to presently, 420 short D2B STEMI interventions were performed
at 5 community hospitals by a single experienced operator creating the SINCERE (Single INdivid-
ual Community Experience REgistry) database.
Results: Median D2B time was 78 min, median procedure time (local anesthesia to recanaliza-
tion) was 13 min; 85.2% of procedures had D2B time <90 min; 95% of the procedures were suc-
cessful – relief of chest pain, >70% ST segment resolution, TIMI 3 ﬂow and Myocardial Perfusion
Grade 3.
Conclusions: Primary PCI with high success rates and predictable short D2B times can be per-
formed with standardized techniques in community hospitals.
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lsevier1. Introduction
Numerous publications and randomized clinical trials have
convincingly demonstrated the superiority of primary angio-
plasty (PPCI) over thrombolytic therapy for ST-elevation
myocardial infarction (STEMI) provided that it is instituted
in a timely fashion (Grines et al., 1993; Zijlstra et al., 1993,
1997, 1999; The Global Use of Strategies to Open Occluded
Coronary Arteries in Acute Coronary Syndromes (GUSTO
230 S. Mehta et al.IIb) Angioplasty Substudy Investigators, 1997; Gibbons et al.,
1993; Andersen et al., 2003; Le May et al., 2001; Schomig
et al., 2000; Kastrati et al., 2002). In a quantitative review
of 23 randomized trials, PPCI was better than thrombolytic
therapy at reducing overall short-term death, 7% vs 9%,
respectively, and also demonstrated improved long-term out-
comes (Keeley Ellen et al., 2003). Several trials have shown
that short door-to-balloon times improve early and late
outcomes in primary PCI (Nallamothu and Bates, 2003;
Cannon et al., 2000; McNamara et al., 2006; De Luca
et al., 2004; Berger et al., 1999; Juliard et al., 2003; Brodie
et al., 2006; O’Neill et al., 2005). Door-to-balloon times of
90 min or less have been shown to be associated with smaller
infarct sizes, fewer major adverse cardiovascular events, and
better long-term survival (Juliard et al., 2003; Brodie et al.,
2006; O’Neill et al., 2005). The National Registry of Myocar-
dial Infarction (NRMI) database demonstrated a strong rela-
tionship between door-to-balloon time (D2B) and in-hospital
mortality among 29,222 patients with STEMI. When treat-
ment was started within 90 min after arrival, in-hospital mor-
tality was 3.0%, but it increased to 4.2%, 5.7%, and 7.4%
with delays of 91–120 min, 121–150 min, and more than
150 min, respectively. After adjustment for differences, each
15-min reduction in door-to-balloon time from was associated
with 6.3 fewer deaths per 1000 patients treated (De Luca
et al., 2004) (Fig. 1). Similarly, 30 day and 1 year mortality
are also proportional to the door-to-balloon time (De Luca
et al., 2004; Berger et al., 1999). With such clear and demon-
strable improvements in morbidity and mortality beneﬁts; it
was a natural transition for guidelines and for practices to
rapidly shift. Based on this data, the American College of
Cardiology (ACC) in conjunction with the American Heart3.0%
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Figure 1 Mortality and myocardial salvage as a function of time to
proportion of myocardium salvaged if reperfusion is attained at very tim
salvaged progressively decreases as the time to reperfusion increases. T
represent in-hospital mortality in the NRMI database, the blue bars
represents 1 year mortality from 6 RCTs of PPCI from the Zwolle g
reperfusion increases, there is a directly proportional increase in in-hos
1997. Pathologic considerations of the surgery of adult heart disease.
Hill, New York, 1997, p. 85; McNamara et al. (2006); De Luca et aAssociation (AHA), as well as the European Society of Car-
diology recommend that primary angioplasty should be done
within 90 min of presentation (or the time from initial medical
contact) (Antman et al., 2004; Van de Werf et al., 2003). The
ACC/AHA guidelines state.
If immediately available, primary PCI should be performed
in patients with STEMI (including true posterior MI) or MI
with new or presumably new LBBB who can undergo PCI of
the infarct artery within 12 h of symptom onset, if performed
in a timely fashion (balloon inﬂation within 90 min of presen-
tation) by persons skilled in the procedure (Antman et al.,
2004).
Data from the National Registry of Myocardial Infarction
(NRMI), however, demonstrates that in 1999 only 35% of pa-
tients undergoing PPCI were treated within the recommended
90-min door-to-balloon time, and improvement from 1999 to
2002 was slow with only 26% of hospitals improved door-to-
balloon time by more than 3 min/year (Smith et al., 2006).
As a result of this remarkable evolution, various changes oc-
curred and are ongoing in the management of STEMI patients.
ACC/AHA Guidelines have established new directives for the
early management of the STEMI patient and have clearly
delineated class I indications including the goal door-to-bal-
loon time (D2B) should be less than 90 min (Antman et al.,
2004) (Table 1). Based on these recommendations and estab-
lished standards of care, other organizations on various levels,
including international, national, and regional have followed
pattern.
1. The United States has taken an early global lead in this
nation-wide quality initiative to provide aggressive manage-
ment for STEMI patients.7%
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reperfusion therapy. The green line schematically represents the
epoints from onset of symptoms*. The percentage of myocardium
he bars represent mortality at various timepoints: The green bars
are 30 day-mortality as a function of D2B, and the yellow line
roup as a function of symptom-to-balloon time–. As the time to
pital, 30 days, and 1 year mortality. Adapted from: *Schoen, F.J.,
In: Edmund, L.H. (Ed.), Cardiac Surgery in the Adult. McGraw-
l. (2004); and –Berger et al., 1999. Circulation 100, 14–20 (294).
Table 1 ACC/AHA guidelines class I indications for STEMI. From: Antman et al. (2004).
Pre-hospital care and transport
1. Patients with symptoms of STEMI should be transported to the hospital by ambulance rather than by friends or relative
2. 162–325 mg of aspirin (chewed) should be administered to chest pain patients suspected of having STEMI by pre-hospital EMS providers,
unless otherwise contraindicated
Emergency department care
3. A 12-lead ECG should be performed and shown to an experienced emergency physician within 10 min of ED arrival on all patients with chest
discomfort
4. Laboratory examinations including cardiac biomarkers should be performed, but should not delay the implementation of reperfusion therapy
5. Portable chest X-ray, should be performed, but should not delay implementation of reperfusion therapy, unless a contraindication is
suspected (i.e. aortic dissection)
6. Routine therapeutic measures should be initiated including: ASA if not given previously, supplemental oxygen for patients with arterial
oxygen desaturation (<90%), nitroglycerin for ongoing ischemic discomfort, morphine sulfate for analgesia, and oral beta-blocker therapy
unless contraindicated
Decision on reperfusion strategy
7. All STEMI patients should undergo rapid evaluation for reperfusion therapy
8. If PCI is chosen as the reperfusion strategy: the goal medical contact-to-balloon, or door-to-balloon times is <90 min
9. If symptom duration is less than 3 h: primary PCI (PPCI) or early transfer of patients to facilities that provide PPCI is recommended if the
expected door-to-balloon time minus the expected door-to-needle time (DTN) is less than 60 min
10. If symptom duration is greater than 3 h: PPCI is generally preferred and should be performed with a medical contact-to-balloon or door-to-
balloon interval as short as possible and a goal of within 90 min
11. Cohort of patients who are still candidates for thrombolytic therapy include: early presentation when there is a delay to PPCI, invasive
strategy is not an option, or there is a delay to PPCI (D2B–DTN time >60 min)
12. PPCI should be performed in ﬁbrinolytic ineligible patients who present with STEMI within 12 h of symptom onset
Other considerations: high-risk subgroups and rescue PCI
13. PPCI should be performed for: (1) patients <75 years old with ST elevation or LBBB who develop shock within 36 h of MI and are suitable
for revascularization that can be performed within 18 h of shock unless further support is futile; patients with severe CHF and/or pulmonary
edema (Killip class 3) and onset of symptoms within 12 h. The medical contact-to-balloon or door-to-balloon time should be as short as possible
(i.e. <90 min)
14. Rescue PCI should be performed in: patients <75 years old with ST elevation or LBBB who develop shock within 36 h of MI and are
suitable for revascularization that can be performed within 18 h of shock unless further support is futile; patients with severe CHF and/or
pulmonary edema (Killip class 3) and onset of symptoms within 12 h
15. In patients previously receiving thrombolytics whose anatomy is suitable, PCI should be performed when: there is objective evidence of
recurrent MI, moderate or severe spontaneous or provocable myocardial ischemia during recovery, or cardiogenic shock or hemodynamic
instability
Optimizing door-to-balloon times for STEMI interventions 2312. In partnership with the AHA and the National Heart Lung
and Blood Institute, the ACC established the D2B: An Alli-
ance for Quality program to promote the cause of short
door-to-balloon times (McNamara Robert et al., 2006).
3. JCAHO and CMS measure door-to-balloon (D2B) times
for STEMI interventions as a key performance indicator
for institutions (D2B Homepage; National Hospital Qual-
ity Measures, 2007).
4. Communities are striving for even lower D2B times.
5. Individual hospitals are scrambling to revamp their STEMI
protocols and improved hospital and systems processes.
6. EMS pathways are being adjusted to triage patients with
STEMI to institutions performing short D2B time STEMI
interventions.
7. A group of early adopters amongst interventional cardiolo-
gists is beginning to develop with the skills and availability
to provide this care.
In order to provide this high level of quality care, all the
individuals must be adequately trained and experienced.
Guidelines have set forth recommendations deﬁning the level
of expertise required of individuals, laboratories, and institu-
tions who partake in STEMI interventions (Antman et al.,
2004). Individuals practitioners should be experienced and per-
form more than 75 PCI procedures per year, of which at least11 should be for STEMI. The laboratory should perform more
than 400 PCI procedures per year, of which at least 36 are pri-
mary PCI for STEMI (Smith et al., 2006). Traditionally the
recommendations are for the laboratory to possess on-site car-
diac surgery capability and back-up, however the new guide-
lines, do permit institutions to consider performing STEMI
interventions without on-site surgical standby under more
strict protocols including:
1. A proven plan for rapid transport to a cardiac surgery
operating room exists in a nearby hospital.
2. Appropriate hemodynamic support capability for transfer.
3. Intervention limited to patients with STEMI or MI with
new LBBB.
4. Interventions performed in a timely fashion (D2B < 90 min).
5. Individual practitioners are similarly experienced to per-
form PCI.
6. The hospital performs a minimum of 36 primary PCI pro-
cedures per year.
2. Materials and methods
In conjunction with the evidence-based guidelines for STEMI
interventions released in August 2004 by the ACC/AHA, the
232 S. Mehta et al.SINCERE (Single INdividual Community Experience REgist-
ry) Database was developed. The SINCERE database com-
prises a prospectively collected database of all primary
angioplasty interventions for STEMI performed by a single,
experienced interventional cardiologist in a little over 4 years
span starting approximately January of 2005. It includes 420
STEMI interventions which were performed at ﬁve commu-
nity, non-teaching hospitals located in South Florida. These
various hospitals included a variety of different hospital struc-
tures including for-proﬁt community hospitals; not for-proﬁt
community hospitals funded by a religious charity, and a pub-
lic city hospital. All ﬁve hospitals have signiﬁcant procedural
volume and have on-site cardiac surgery back-up. This work
has remained completely unfunded and largely the efforts of
the author and his staff. Although it is neither a substitute
for published guidelines, nor can it replace lessons learned
from randomized clinical trials, the SINCERE database pro-
vides a rich and illustrative view of the developing state of
acute coronary interventions. It provides some insight into cur-
rent and future areas for improvement. The primary goal of
assembling the SINCERE database was to ultimately improve
the quality of care delivered for patients with acute ST-eleva-
tion transmural myocardial infarction, on both an institutional
and individual level. We hoped to achieve this goal by ﬁrst
obtaining a better understanding of current critical, real world
issues and dilemmas regarding the management of STEMI
interventions. Then identify areas for improvement, and ﬁnally
arrive at some answers and institute these into practice.
Whereas the advantages of early, prompt intervention for
ST-elevation myocardial infarction are clear, the logistics of
providing this care are challenging. Initially, in the SINCERE
database, numerous early hurdles and delays were encountered
and the difﬁculty of achieving the stated goal of
D2B < 90 min was evident. At one of the primary hospitals,
the rate of D2B times within 120 min was 58%, with the rate
of D2B < 90 min being much lower. There were numerous
challenges including a lack of motivation on the part of some
individuals. There was a lack of coordination between the var-
ious components and providers, for example, between the
emergency room and cardiovascular lab (CVL) personnel
and cardiologist. Delays in transport or waiting for personnel
particularly on off-hours occurred too frequently. Rapid pri-
mary coronary intervention incorporates multiple challenges
at various levels including the community, hospital/institu-
tional, cath lab team and personnel, as well as the interven-
tional cardiologist.
There have been various tested strategies recommended in
order to decrease door-to-balloon time (D2B) (McNamara
Robert et al., 2006; D2B Homepage; National Hospital
Quality Measures, 2007; Williams et al., 2005; Bradley et al.,
2005). Many of the initial studies proving the efﬁcacy and abil-
ity of certain strategies were performed at academic hospitals
or communities with strategies in place. The incorporation of
these innovative tactics to shorten door-to-balloon times into
clinical practice is ongoing and evolving. It involves a signiﬁ-
cant amount of teamwork amongst emergency medical service
(EMS) providers, emergency department (ED) personnel and
physicians, the cardiovascular lab personnel (CVL), and the
interventional cardiologist. We wished to explore certain as-
pects of providing 24/7, short D2B STEMI interventions at
non-teaching community hospitals including: the feasibility
of early activation by EMS, early triage and accelerated algo-rithms for treatment of STEMI, and early transfer of STEMI
patients to a PPCI facility. During the course of the database,
a clear focus was placed on improving D2B times at all of the
institutions involved. As expertise increased, and efﬁciency im-
proved from better teamwork, from early activation of PPCI
protocols and from the application of standardized techniques,
our D2B times improved and D2B times of less than 90 min
became a norm.
On an individual provider level, we wish to improve the
efﬁciency of providing acute MI care, by streamlining the
decision tree and providing a standard protocol, while rec-
ognizing that sometimes deviations for certain aspects of
the protocol may be necessary. We wish to develop and
sustain:
1. An efﬁcient, appropriate and consistent pharmacological
strategy for the management for STEMI interventions.
2. Standardize techniques to achieve high D2B success rates
and maintain low procedure times.
3. Solidify a strategy for stenting and determining the type of
stent deployed.
We hope that the data and expertise acquired from the SIN-
CERE database will provide some educational information
and training concerning STEMI interventions.
3. Results
Overall, a total of 420 patients underwent primary PCI for
STEMI in the last 4 years and they were included in the
SINCERE database. The patients had a mean (±SD) age
of 64.9 ± 13.3 years and most were males (67.6%). Given
the multiethnic demographics of the South Florida popula-
tion, a signiﬁcant proportion of patients (58.4%) were of
Hispanic origin (Table 2). Our cohort of patients had signif-
icant underlying coronary risk factors with 69.1% of the pa-
tients having hypertension; 68% were smokers, and 54.8%
were diabetics. A signiﬁcant proportion also had a previ-
ously known history of CAD with 21.6% of patients having
a prior PCI. The majority of patients presented off-hours.
Data pertaining to the timeframe from symptom onset to
presentation time was not collected. Within our cohort of
patients, there appear a considerable number of patients
with high-risk clinical features. A signiﬁcant proportion of
patients presented with cardiogenic shock 13.4%, and a
small proportion presented post-cardiac arrest and resuscita-
tion or for rescue PCI given failed reperfusion, persistent
and/or recurrent ischemia.
At the time of angiography, identiﬁcation of the culprit le-
sion demonstrated the following distribution: LAD 39.1%;
LCX 12.7%; RCA 42.8% (Table 3). A small proportion of
patients had prior coronary bypass surgery, and 3.3% of the
total population underwent intervention of a saphenous vein
bypass graft. Two elderly patients presented with anterior
MI and cardiogenic shock and underwent successful interven-
tion of an unprotected LMCA 0.4%. On initial angiography,
the culprit vessel was found to have totally occluding culprit
lesions with distal TIMI 0-1 ﬂow in the majority of the patients
(80%). Overall, there was a signiﬁcant amount of thrombus
visualized in this cohort of patient. Although, the amount of
thrombus was graded at the time of angiography, it was not
routinely recorded.
Table 2 Demographic and clinical characteristics from SIN-
CERE database (n= 420).
Variable
Age (yr) – (Mean ± SD) 64.9 ± 13.3
No. (%)
Ethnicity
Hispanic 243 (58.4)
White American 80 (19.2)
African American 63 (15.4)
Asian 17 (4.2)
Other 12 (2.8)
Male sex 281 (67.6)
Risk factors
Hypertension 290 (69.1)
Diabetes Mellitus 226 (54.8)
Previous PCI 89 (21.6)
Smoking 285 (68)
Arrival to ER
On-hours (7 am–6 pm) 248 (59.2)
Oﬀ-hours (6 pm–12 am) 121 (16.6)
Oﬀ-hours (12 am–7 am) 101 (24.2)
Cardiogenic shock 56 (13.4)
Table 3 Angiographic characteristics in SINCERE database.
No. (%)
Culprit lesion distribution
RCA 176 (42.8)
LAD 164 (39.1)
LCX 54 (12.7)
Left main 6 (1.2)
Ramus Intermedius 3 (0.8)
SVG 14 (3.3)
Visible thrombus 281 (67.7)
Totally occluded culprit 256 (61.4)
TIMI ﬂow (pre-procedure)
TIMI 0 255 (61.0)
TIMI 1 80 (19.0)
TIMI 2 51 (12.4)
TIMI 3 27 (6.6)
Table 4 Medications, anticoagulation, and antiplatelet ther-
apy in SINCERE database.a
No. (%)
Anticoagulation
Bivalirudin 407 (97)
Heparin 13 (3)
Antiplatelets
GIIb/IIIa inhibitors
Abciximab 194 (46.2)
Eptiﬁbatide 25 (6.1)
Clopidogrel (load dose)
300 mg 218 (52.4)
600 mg 202 (47.6)
Intracoronary vasodilators
Nipride 298 (71.3)
a Aspirin use was universal; data was not tabulated on use of
beta-blocker, ACE-I, NTG, statins, or other treatments.
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onstrate a few interesting points of note. Traditionally, unfrac-
tionated heparin is the recommended anticoagulant of choice
in the setting of STEMI, with low molecular weight heparin
an alternative (Antman et al., 2004; Van de Werf et al.,
2003; Smith et al., 2006). Direct thrombin inhibitors, such as
bivalirudin, are an alternative in the setting of heparin induced
thrombocytopenia. Until recently, no large randomized studies
had been published on the routine use of bivalirudin in STE-
MI. Despite this, our anticoagulation strategy in STEMI over
the past 4 years has largely relied on the use of bivalirudin.
This is based on various points including our familiarity with
the agent (Minutello et al., 2003), its ease of use, consistent ef-
fect, low side effect proﬁle, and favorable clinical results in thesetting of ACS from randomized controlled trials (Stone et al.,
2006). We felt that the beneﬁts seen in large randomized con-
trolled trials of acute coronary syndrome patients should
extrapolate to the setting of STEMI. This was supported by
some smaller studies using bivalirudin in STEMI (Stella
et al., 2004). Indeed, the majority of the patients in the data-
base 407/420 (97%) received bivalirudin as the anticoagulant
of choice (Table 4). A small percentage of patients initially re-
ceived unfractionated heparin and were subsequently switched
to bivalirudin. A handful of patients who had been started on
unfractionated heparin at the transferring facility, and had an
elevated ACT at the time of PCI, were subsequently kept on
intravenous heparin. In addition to bivalirudin, Aspirin was
uniformly administered and clopidogrel was administered in
a majority of the cases. In regards to the timing of the clopido-
grel, the majority received an initial 300 mg bolus in the ER
upon diagnosis, and 47.6% of patients received an additional
300 mg after PCI for a total dose of 600 mg. A glycoprotein
IIb/IIIa inhibitor (GIIb/IIIa) was used in 52.3% of patients,
of which the majority were also on combination therapy with
bivalirudin. In the majority of cases, GIIb/IIIa agents were
started upstream prior to the PPCI. The predominant GIIb/
IIIa agent used was abxicimab, accounting for 46.2% of cases
in which GIIb/IIIa was administered. Eptiﬁbatide was used in
the remaining patients that were treated with a GIIb/IIIa
agent.
Review of the procedural characteristics demonstrated
some interesting points (Table 5). All procedures were per-
formed with a 6F device. In an overwhelming majority of
cases, either a JL4 or JR4 guiding catheter was used, depend-
ing on whether the culprit lesion was in the left coronary artery
or right coronary artery distribution, respectively. A monorail
system was used exclusively and hydrophilic guidewires were
used in the majority of the cases with all wires being 182 cm
in length. Rarely was the initial wire unable to cross the lesion
or did it need to be exchanged for some other reason. We had
no cases of coronary perforation and/or dissection. Given the
signiﬁcant degree of thrombus burden noted during the cases,
additional adjunctive devices were used in 251 patients,
roughly 60% of cases. A large proportion of these cases was
performed using an aspiration catheter, of which various
Table 5 Procedure characteristics from SINCERE database.
No. (%)
Procedural characteristics
Stenting 394 (94.4)
PTCA/thrombectomy only 26 (5.6)
Direct stenting 122 (29)
Prior thrombectomy/aspiration 298 (71)
Devices used
Guiding catheter
JR-type (RCA lesion) 154/176 (88)
JL-type (LCA culprit-LM, LAD, or Cx) 197/227 (87)
Hydrophilic wires 382 (91.1)
Aspiration catheters 184 (44.6)
Export 151/232 (64.6)
QuickCat 42/232 (18.2)
Pronto 37 (16.2)
Angiojet 66 (15.7)
Closure device 344 (82.5)
Intraortic balloon pump 37 (9.2)
Intracoronary nitroprusside 298 (71.3)
Procedural results
Procedure success rate 96.6
TIMI 3 ﬂow 399 (95)
Myocardial Blush Grade 3 352 (84)
Sub-acute stent thrombosis 2 (0.47)
In-hospital mortality 14 (3.4)
Table 6 Stenting characteristics from SINCERE database.
Stenting characteristics No. (%)
Vessel stented
Culprit 355 (89.4)
Additional vessel PCI 39 (10.6)
Type of stent (culprit)
BMS 240 (61.0)
DES 153 (39.0)
No. of stents used
1 323 (81.9)
2 66 (16.7)
3 or more 5 (1.9)
Stent length (mm)
<10 2 (5.2)
10–20 208 (71.1)
20–30 82 (21.3)
>30 21 (5.4)
Stent diameter (mm)
2.0–2.5 9 (1.9)
2.5–3.0 106 (26.9)
3.0–3.5 232 (58.8)
3.5–4.0 67 (16.9)
Percentages and averages are based on the available patient
information.
Table 7 Procedure results from SINCERE database.a
Overall procedure success No. (%)
TIMI 3 ﬂow 399 (95)
MBG 3 352 (84)
Median D2B time Minutes
All patients 78
First 200 patients 87
Last 200 patients 68
Mean procedure time 13.2
a Percentages and averages are based on the available patient
information.
234 S. Mehta et al.different catheters were employed including: Export (Med-
tronic, Minneapolis, MN), Pronto (Vascular Solutions, Min-
neapolis, MN), and QuickCat (Kensey Nash, Exton, PA)
aspiration catheters. Alternatively, rheolytic thrombectomy
was performed in 66 patients employing the Angiojet (Possis
Medical, Minneapolis, MN) which represents 15.7% of the
overall study database. Distal protection devices were not
used. Adjunctive vasodilator therapy with intracoronary ni-
pride was used in more than half (71.3%) of cases. More than
two-thirds of patients underwent arteriotomy closure with per-
cutaneous closure devices (82.5%).
Table 5 provides a breakdown of the stenting characteris-
tics in our population of PPCI. Although stenting was per-
formed in the majority of patients, 9% of patients underwent
angioplasty alone, for a variety of reasons including: throm-
bectomy alone, small target vessel, or inability to pass stent.
Direct stenting, without pre-dilation, was achieved in 29% of
patients overall, of which roughly a third had undergone
pre-treatment with an aspiration or thrombectomy device. Of
those patients who underwent stenting, drug-eluting stents
were used to treat the primary culprit lesion in 64.8% of pa-
tients overall. The choice of drug-eluting stent was distributed
between the three commercially available drug-eluting stents
(Table 6). BMS were used in 35.2% of culprit lesions, and a
small percentage of cases 4.1% used both a drug-eluting and
a bare metal stent. The majority of patients had one stent
placed, but in 18.6% of patients multiple stents were used
and 3.0–3.5 mm stents used in 58.8% of cases. Non-culprit le-
sion angioplasty and/or stenting were performed in a minority
of cases (11.6%) because of high grade lesions with impending
closure, or electrocardiographic changes in the respective terri-
tory of myocardium involved. Two patients (0.8%) were re-
ferred for emergent coronary bypass graft surgery.A review of safety concerns demonstrated that the rate of
complications or MACE was low (Table 9). Bleeding compli-
cations were rare. There was one retroperitoneal hematoma,
otherwise there was no other major bleeds, intracranial bleed,
bleeds requiring blood transfusion, or lethal bleed. There were
no cerebrovascular events, either hemorrhagic or ischemic.
Although, serial cardiac enzymes in the post-PCI period were
not routinely recorded, clinical reinfarction was rare with
sub-acute stent thrombosis and abrupt closure occurring in
two patients (0.47%). Reviewing the two cases of sub-acute
stent thrombosis, they both occurred within 48 h, and one
was deemed to be the result of an undersized stent, while the
other was due to large residual thrombus load. The rate of
overall in-hospital death was 3.4%.
The majority of the procedures (95%) were successful,
based on relief of chest pain, >70% ST segment resolution,
TIMI 3 ﬂow and Myocardial Perfusion Grade 3 (Table 7).
Of particular concern given the recent guideline recommenda-
Table 9 Hospital course and long-term follow up from
SINCERE database.
No. (%)
In hospital events
Massive bleedinga 2 (0.47)
CVA 0 (0)
Sub-acute stent thrombosis 2 (0.47)
In hospital death 14 (3.4)
Procedural death 10 (2.4)
Length of stay
63 days 201 (47.6)
P7 days 72 (17.3)
4–6 days 147 (35.1)
a Deﬁned as life-threatening bleeding requiring blood transfusion.
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loon time as the time from arrival to the time of reestablishing
TIMI 3 ﬂow in the culprit artery. For the SINCERE database
as a whole, the median D2B times was 78 min with 58.2% of
procedures having D2B time <90 min. However, there was a
signiﬁcant time-dependent effect over the course of the data-
base. If we examine the cases in 50 case intervals we could
see deﬁnite improvement over the course of the study. Whereas
for the ﬁrst 100 cases the median D2B was 120 min with less
than a quarter of patients having D2B < 90 min, over the last
120 procedures D2B time <90 min was achieved in greater
than 90% of the procedures (Table 8). We deﬁned procedure
time as the interval from administration of local anesthesia
to successful reperfusion of the culprit infarct-related artery
(IRA). Of note, this may be different from other deﬁnitions
of procedure time which take into account the entire interven-
tional procedure. Our measured mean procedure time was
13.2 min for the entire cohort. Similar to the D2B, procedure
time demonstrated a continued improvement and decrease in
procedure times over the course of the database while main-
taining overall high procedural success. Approximately two-
thirds of patients were discharged within 4 days of hospital
admission (Table 9).
Overall, we understand some of the limitations of the data-
base. In the initial lead in phase for the study, some of the data
was by necessity collected retrospectively and thus, some data
sets were incomplete. In addition, certain markers and data
were not routinely recorded initially, but only subsequently be-
came a standard within the database. For example, although
myocardial blush grade and myocardial perfusion may have
been evaluated initially, we only started to routinely record it
in a prospective fashion after the ﬁrst 80 cases. This makes sta-
tistical comparisons difﬁcult particularly when using the data
from the initial portion of the study. We based our percentages
upon the portion of patients for which data was available.
Although it was not a randomized study and therefore cannot
be used to compare the efﬁcacy of different treatments or strat-
egies, the database does demonstrate that certain treatment
strategies and procedures can be utilized clinically safely with
good procedural results and long-term outcomes. We also
acknowledge the ﬂaw and bias that a single operator study
may introduce, however, there was no commercial support
or ﬁnancial incentives, therefore eliminating any source of
bias. The experience by itself creates a very unique and power-
ful advantage. The SINCERE database is a rough estimation
of our clinical experience in performing STEMI interventions
over the past 4 years. Indeed, it may be beneﬁcial for each pro-
vider to construct a similar database or experience log. Similar
to the concept of registry data like the NCDR, it may be ben-
eﬁcial to compare one’s own results to national standards of
care and norms as well as evolving trends. In addition, practi-
cal experience may provide some guidance where there are noTable 8 Temporal trends from the SINCERE database.
Cases Median D2B (min) D2B < 90 min (%)
1–100 120 21.6
101–200 109 42.6
201–300 89 76.0
301–400 68 94.5
401–420 83 95.8randomized clinical trials to offer deﬁnitive answers, and likely
will never be. For example, guide catheter selection and guide-
wire selection will unlikely show a statistically signiﬁcant dif-
ference in morbidity or mortality. Many of these decisions
largely remain a question of operator preference and/or expe-
rience. As an ongoing database, it may be useful to compare
these results over time.
4. Discussion
Early on, during the evolution of the SINCERE database sev-
eral questions arose:
1. What is the ideal metric to measure and analyze?
2. Is it D2B? Procedure time? Technical success?
These questions are not unique to the database itself, how-
ever. As the area of STEMI interventions has developed and
evolved, greater scrutiny has been focused on consistently
achieving measures of success. But what is the deﬁnition of a
successful intervention? Although there are suggestions from
various committees, no uniform deﬁnition exists that com-
pletely deﬁnes a STEMI success. Reviewing the database dem-
onstrated this ﬂaw. All ﬁve institutions where STEMI
interventions were performed had no standard deﬁnition of
success. Too many hospitals and institutions are measuring dif-
ferent criteria to tout their success in short D2B STEMI inter-
ventions. In ways, this situation mirrors the imprecise deﬁnition
of stent thrombosis prior to the Academic Research Consor-
tium (ARC) guidance. These indeed are general questions
which must be answered in the cardiology community, particu-
larly given the push towards pay-for-performance measures,
ongoing reviews of hospital based processes, and the need to
standardize measures for research applications. Indices ofMean procedure time (min) Procedure success (%)
30.3 91.1
21.1 95.8
17.4 100
14.2 98
19.0 99
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It is crucial to distinguish and differentiate two metrics which
are particularly important to the interventional cardiologist:
1. Recanalization time and/or success.
2. Procedure success.
4.1. Recanalization time
Let us examine, from a pragmatic perspective, the recanaliza-
tion time. Recanalization is deﬁned as the restoration of epi-
cardial coronary ﬂow and, therefore recanalization time
refers to the time that is required to reestablish ﬂow in a pre-
viously occluded artery. But when does the clock start and
stop? Occlusion roughly coincides with symptom onset, and
it is at this point when the clock starts. It is precisely at this
point when the myocardium is placed in jeopardy if reperfu-
sion is not established promptly. It is assumed that in PPCI,
upon inﬂation of the ﬁrst balloon epicardial ﬂow is instanta-
neously reestablished. In this manner, D2B has become a mea-
sure of the recanalization time. However, it does not take into
account the whole ischemic time. Symptom-to-reperfusion, or
total ischemic time, would be a better measure of the degree of
myocardium at risk. However, recollection of precise symptom
onset is often imprecise and relies on patient recall. In addi-
tion, the symptom-to-presentation time is highly variable as
well and depends on patient awareness, identiﬁcation of symp-
toms, and early, prompt presentation to medical care. There-
fore, to use symptom-to-reperfusion time, or symptom-
to-balloon time in the setting of PPCI, as a measure of quality
of care introduces variables into the equation which are out of
the control of the individual provider or the institution.
D2B (or medical contact-to-balloon time) has then become
a measure of the quality of care, and efﬁciency with which var-
ious hospitals and institutions provide care. However, even this
deﬁnition is far from clear. A recent center for Medicare and
Medicaid Services – CMS/JCAHO Joint Task Force recom-
mendation has also struggled with this concept. In one
review, there was only moderate agreement between D2B times
reported to the Hospital Quality Alliance (HQA) and the
National Cardiovascular Data (NCDR) by the same group of
hospitals leading to substantial differences in rankings of hos-
pital performance between data sources (Nallamothu et al.,
2007). The CMS/JCAHO Joint Task Force cited ‘‘compound-
ing difﬁculties in assessment and utilization of D2Bmetrics’’. In
order to deﬁne exactly the ‘‘balloon time’’, the CMS/JCAHO
Joint Task Force committee pondered:
1. ‘‘Is it attainment of TIMI 3 ﬂow (problem of ‘‘no-reﬂow’’
often seen post-stent placement)?’’
2. ‘‘Could it occur with wire crossing and subsequent attain-
ment of TIMI 3 ﬂow?’’
3. ‘‘Is it balloon inﬂation with or without TIMI 3 ﬂow?’’
4. ‘‘Is it stent placement rather than pre-dilation with
balloon?’’
5. ‘‘Can use of intracoronary thrombectomy devices attain
TIMI 3 ﬂow with or without follow-up stent placement?’’
Therefore, while D2B has become a mandated metric, some
minor disagreement exists about which precise event consti-
tutes recanalization. Is it recanalization during guide wirepassage, during balloon angioplasty, atherectomy or during
stenting? The report also mentions of ‘‘anecdotal reports of
‘‘gaming’’ by some operators inﬂating angioplasty balloons
in the aorta or in a ‘‘non-culprit’’ portion of the coronary ar-
tery.’’ From our standpoint, recanalization should be any
event that establishes TIMI 2 or 3 ﬂow. Overall, the symp-
tom-to-recanalization time estimates the duration of ongoing
ischemia and infarction and can be broken down into various
components (Antman et al., 2004). In the setting of primary
PCI, recanalization time is then the sum of three different met-
rics, the symptom onset to presentation (door) time, door to
procedure time, and the procedure time, which includes all
necessary maneuvers to restore TIMI 2-3 ﬂow. In order to
measure the efﬁciency of the hospital, door-to-balloon time
should be the metric assessed. Indeed, it is critical, in that it de-
notes completion of hospital and systems processes and the
culmination of the effort that began with the early activation
of the CVL team and is a good measure of the efﬁciency of
the system. It is also the perfect measure for the D2B and de-
spite the ‘‘gaming’’ of the system by both the interventional
cardiologist and by the institution; this metric is an extremely
powerful tool.
4.2. Procedure time
It is a fallacy, however, to rely solely on the D2B metrics as a
surrogate for success. Recanalization of the IRA may be all
that is needed to measure D2B times but it may not necessarily
deﬁne a successful procedure. A successful procedure must
convincingly demonstrate that various additional angiographic
and clinical parameters have been successfully met as well. The
second metric then is procedural success. Again although the
deﬁnition of procedural success may vary, we take it to denote
establishment of TIMI 3 epicardial ﬂow and adequate myocar-
dial perfusion as evident by myocardial Blush Grade 3, as well
as resolution of chest pain and ST-segment elevation. All crite-
ria must be met to deem the procedure an ultimate success.
Each one of these measures has independent prognostic value
in risk-stratiﬁcation and predicting early and late outcomes for
STEMI patients (De Lemos and Braunwald, 2001; Mehta
et al., 2003; Stone Greg et al., 2002). In addition, while the
D2B is a superb metric for the hospital and system process,
the procedure time may be a rough objective measurement
of the CVL personnel, and in particular, the interventional car-
diologist’s skills. Over the last 100 cases within the SINCERE
database: procedural success was obtained in greater than 95%
of cases; mean procedure times were 13.2 min and
D2B < 90 min were achieved in greater than 90% of the pro-
cedures. As compared to the initial experience, there has been
signiﬁcant improvement in all three parameters. However,
where can further improvement be obtained?
5. Symptom-to-presentation time
Whereas there was signiﬁcant variability in D2B between insti-
tutions, the procedure times were more manageable and ﬁxed.
As the procedural success rate approaches 100%, and the pro-
cedural time approaches an absolute minimum, the logical
answer would be to strive for shorter symptom-to-medical
contact and subsequently medical contact-to-cath lab times.
Further, the very deﬁnition of success may vary depending
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and procedural success are not mutually inclusive or exclusive.
Three hypothetical examples may better elucidate this point.
One can envision a middle-aged male smoker with a history
of hypertension but no prior known coronary disease who is
suffering an acute anterior wall ST-elevation myocardial
infarction. In the ﬁrst scenario, he develops anginal chest pain
early in the morning, however, he only presents to the ED 6 h
later after the symptoms fail to resolve. He arrives in the day-
time on-hours, an ECG is promptly performed in the ED dem-
onstrating the acute infarction, and the emergency room
physician activates the cath lab and notiﬁes the interventional
cardiologist. The patient is taken emergently to the lab and
60 min after his initial presentation to the ED, TIMI 3 ﬂow
is established with an initial balloon pre-dilation and he subse-
quently receives a bare metal stent. His hospital course is
uneventful and he is discharged on day 3.
In this ﬁrst example, the procedure by all accounts is a
success with short door-to-balloon times and technical suc-
cess. However, given the late presentation, the amount of
myocardium salvaged and the results of the revascularization
may be suboptimal regardless. The ﬁrst component of the
symptom-to-balloon time is the symptom-to-medical contact
or presentation time which involves early recognition of
symptoms of STEMI by the patient or someone with the pa-
tient and prompt activation of the emergency response sys-
tem. Whereas the ACC–AHA have established a goal of
5 min from the time of symptom onset to the time the patient
responds and activates the emergency response system (Ant-
man et al., 2004), the average STEMI patient does not seek
medical care until approximately 2 h after symptom onset
(Rogers et al., 2000; Goff et al., 1999; Welsh et al., 2003).
In the Global Registry of Acute Coronary Events (GRACE)
project the mean and median delays for patients with STEMI
were 4.7 and 2.3 h, respectively, and only 41% of patients
with STEMI presented within 2 h of onset of ischemic symp-
toms (Goldberg et al., 2002). Accordingly, there are national
efforts and patient education campaigns to inform patients
regarding the signs and symptoms of MI and the appropriate
course of action (Faxon and Lenfant, 2001; National Heart,
Lung, and Blood Institute, 2007; Wenger, 2004). Although
it is a class I recommendation that patients with symptoms
suggestive of a possible STEMI should seek medical attention
promptly by activating the emergency response system, only
anywhere between 23% and 53% of patients suffering from
STEMI use EMS (Burwen et al., 2003; Canto et al., 2002).
Most patients either driving themselves or having a friend
or family member take them. There was a signiﬁcant geo-
graphic difference in these trends (Brown et al., 2000). Given
South Florida’s multicultural background, it would be inter-
esting to assess social, ethnic and racial variations of the
availability and utilization patterns of healthcare resources
within this community. This information may be very useful
in order to educate particular patient populations and to
identify cultural, language, political, and/or ﬁnancial barriers
that may exist to access and/or utilization of care.6. Medical presentation-to-cath lab
Once the STEMI patient accesses the medical healthcare sys-
tem, whether it is by calling 911, walking into the ED or anoutside clinic, the goal is to reach a diagnosis and deliver treat-
ment as soon as possible. Recalling our previous theoretical
case, one can envision an alternative scenario.
Our previous patient calls 911 soon after symptom onset
within 30 min. He is brought to the ED and the initial
ECG demonstrates acute infarction. However, there is a de-
lay in activation of the cath lab and the balloon inﬂation
does not establish TIMI 3 ﬂow until 120 min after initial
presentation. Regardless, of the initial delay, the rest of
the procedure proceeds uneventfully, he receives the same
bare metal stent, and is discharged home in good condition
in 3 days.
In this scenario, although the patient presented early in the
course of his infarct and the procedure was ultimately success-
ful, the initial hospital course was suboptimal and failed to
meet the new recommended standard of care. The door-to-bal-
loon time was too long, and this delay mitigates the ultimate
beneﬁt of revascularization. There have been various tested
strategies recommended in order to decrease door-to-balloon
time (McNamara et al., 2006; Nallamothu et al., 2005; Bradley
et al.,2005, 2006; Khot et al., 2007). Many hospitals are incor-
porating these innovative techniques in order to shorten D2B
times for STEMI interventions. Experience of the staff, per-
sonnel, and physicians is critical in performing STEMI inter-
ventions in an expeditious, yet efﬁcient manner and
ultimately for the success of the procedure. Accordingly, the
ACC/AHA established minimum suggested requirements for
each of these (Smith et al., 2006). STEMI interventions can
safely be performed with short D2B times and very high suc-
cess rates and low procedure times at most community hospi-
tals if they have:
1. A closely coordinated system involving teamwork amongst
the EMS, ED and the CVL.
2. Sufﬁcient volume of PCI.
3. Operators sufﬁciently experienced in the procedures.
4. Preferably have on-site cardiac surgery, although, if not
have a well established plan for referral and transfer in case
the necessity arises.
The role of EMS in providing fast and effective care for
AMI should not be understated. They often have the initial
contact with the patient and therefore triage of the patients
to appropriate institutions is essential. Pre-hospital ECGs
are fundamental for this capacity. Indeed the ACC/AHA
guidelines state the goal of medical contact-to-balloon times
of 90 min (Antman et al., 2004) Therefore, in the setting in
which the patient with STEMI is brought by EMS, the clock
has already started ticking even before the patient arrives at
the hospital. As in other parts of the nation and the world,
in south Florida, the community served by the SINCERE
database, the EMS system is cognizant of triaging STEMI
patients to institutions performing 24/7 STEMI interven-
tions. However, 70% of hospitals nationally do not have
these capabilities. Therefore, as some hospitals develop the
capability to deliver PPCI services either with or without
on-site cardiac surgery back-up, and communities develop
referral patterns to facilities capable of PPCI or between
facilities, the dynamics of PPCI care within the US contin-
ues evolving. In developing national and community-based
strategies for the treatment of STEMI, several questions
arise:
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excellence, where the STEMI patient will be preferably
taken to by EMS?
2. Is the STEMI model headed to become like Level 1 Trauma
Centers with preferred triage of the STEMI patient to these
skilled centers?
3. How would EMS determine to which institute the transfer
occurs?
4. How much patient preference will exist?
5. Would CMS and other payers mandate this care be admin-
istered at specialty institutions?
Indeed, there are various questions which remain to be an-
swered. There is a call for regionalization of care with the
establishment of centers of excellence (Topol and Kereiakes,
2003; Califf and Faxon, 2003; Rokos Ivan et al., 2006). Vari-
ous communities have been successful in establishing effective
protocols based on either an inter-hospital transfer system or
pre-hospital cardiac triage. Interhospital transfer has been
demonstrated effective in various communities, most promi-
nently in Minnesota (Henry et al., 2007; Ting et al., 2007).
Pre-hospital cardiac triage of STEMI patients to centers offer-
ing PPCI has also effective in various communities, and re-
quires a pre-hospital 12-lead ECG (Gross et al., 2007; Le
May et al., 2006; Swor et al., 2006). Recently, this model has
been effective in the Southern California community to achieve
an average 85% D2B < 90 rate within 4 counties surrounding
Los Angeles (Rokos, 2007). It relies signiﬁcantly on qualiﬁed
EMS personnel and eliminates considerable amount of delay
by allowing for parallel activation of the cath lab while trans-
port is ongoing. The most effective pattern of referral and tri-
age may be different in a rural area as compared to a large,
suburban metropolitan area, therefore, out of necessity or
practicality each individual community the answers may be
different. Chapter 22 will discuss some of these matters in more
details.
For primary PCI, the overall efﬁciency of the process can
be assessed by evaluating the D2B time. In order to better
understand where the delays are occurring, the D2B time can
be broken up into its constituents, It can be sliced up in various
ways. An effective way is to split up D2B time is divide it into:
ED time, response time by the cath-lab personnel and interven-
tional cardiologist and, ﬁnally the cardiovascular lab (CVL)
procedure time. A rough estimate at a good program would
be to split the 90 min across these 3 areas. The most efﬁcient
way would be to leave 45 min for the CVL procedure time.
Once you break up the procedure into these three components,
it becomes very easy to get a snapshot of the entire process.
Within these three components of the D2B time are hidden
the areas to monitor results and the speciﬁc indices for perfor-
mance improvement. The ACC’s D2B: An Alliance for Qual-
ity program provides hospitals with key evidence-based
strategies and supporting tools needed to help reduce D2B
times to a standard of <90 min 100% of the time (D2B Home-
page). Various strategies have been advocated to improved
D2B: An Alliance for Quality advocates the adoption of six
core strategies for reducing door-to-balloon times:
1. ED physician activates the cath lab.
2. One call activates the cath lab.
3. Cath lab team ready in 20–30 min.
4. Prompt data feedback.5. Senior management commitment.
6. Team-based approach.
Criteria for the establishment of an ideal primary PCI cen-
ter have been suggested (Le May et al., 2006). After the
announcement of the new guidelines, there were compulsive
bi-weekly meetings to review these metrics in some of the insti-
tutions where the SINCERE database was created from. Spe-
ciﬁc shortcomings were identiﬁed, and performance
improvement initiatives were undertaken. If the ﬁrst interval
of the ED is continuously prolonged and it is prolonging the
D2B times, then attention needs to be focused on the ED pro-
cesses. ED activation of the cath lab has become the norm at
all ﬁve institutions participating in PPCI programs. Other op-
tional strategies include a pre-hospital ECG to activate the
cath lab and an on-site cardiologist 24/7. These other strategies
have been used variably. We tried to demonstrate from a sub-
set of STEMI patients the beneﬁts of having an in-house Inva-
sive Cardiology Team for ultra Shortened Door-to-Balloon
Times (<30 min). We will discuss some of these strategies to
reduce D2B times in further detail in following chapters.
A trade-off of short D2B times for STEMI interventions
occurs in terms of high false alarms or the lack of a ‘‘culprit’’
lesion by angiography. Often, this occurs from incorrect diag-
nosis; seldom from a recanalized vessel and sometimes simply
because of the rush to push the ‘‘Code Heart’’ button. It must
be recognized that several ED staff and ED physicians are un-
der severe pressure from various sources to deliver ultra-short
times and it is not surprising to see very high false alarms at
certain institutions. The ACC/AHA guidelines leave a leeway
of 20% false alarms (Antman et al., 2004). Nationally, the rate
of patients taken emergently for acute primary coronary inter-
vention and found to have normal coronaries is approximately
10% based on data from the NCDR, however, at some insti-
tutions, this number may run much higher. In the Southern
California experience, of patients triaged for PPCI for pre-
sumed STEMI, 23% of patients did not receive PPCI for some
reason (Rokos, 2007). ECG identiﬁcation of true MI from nor-
mal variants or mimics is essential and often relies on making a
correlation between the clinical picture and interpretation of
the ECG. Although perhaps not as hazardous as missing an
MI on ECG, the rate of false alarms is an informative indica-
tor to gauge the abilities of an emergency department (ED)
staff, in particular the ED physician. Having sufﬁciently
trained ED physicians is of particular importance if various
practices such as ED physician activation of the cath lab pro-
gress to become the standard of care. Similarly, in the case of
pre-hospital ECG, having physician oversight and interpreta-
tion or sufﬁciently trained EMS personnel is critical to overall
success of the strategy.
Once the cath lab is activated, the response time by CVL
personnel and the interventional cardiologist is essential. In
fact, the largest area of improvement in the D2B process at al-
most each institution exists in the Response Time to reach the
CVL by the Interventional Cardiologist and the CVL Team.
This area has received considerable attention in numerous
publications and makes particularly dramatic differences be-
tween D2B times ‘‘on-hours’’ and during ‘‘off-hours’’ (Wil-
liams et al., 2005). Within SINCERE, there was tremendous
variability within this metric. This metric is also an excellent
way to measure teamwork that exists at institutions that per-
form STEMI interventions. Hospitals desiring to improve their
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sible. Physician and staff motivation is a large determination
for this metric and very strict and frequent monitoring of these
time intervals is critical. This metric is also a good way to track
physician and staff performance. One of the author’s recom-
mendations is for the creation of differential D2B times:
<60 min during ‘‘on-hours’’ and <90 min during ‘‘off-
hours’’. So, Institutions that are struggling with D2B times
should immediately start by achieving D2B during ‘‘on-hours’’
and then continue working on the improvements during ‘‘off-
hours’’.
To understand its dynamics, to master this component and
to reduce it to the lowest possible denominator, the author
slept in-house for several nights. Various institutions in the
country are experimenting innovative approaches, including
cross training other staff for CVL operations, in-house CVL
teams, besides the author’s own experiment which are some
of the interesting strategies that will be used to reduce Re-
sponse Times.
7. Cath lab time
In yet a third scenario, the patient again calls 911 early after
symptom onset. This time, a pre-hospital 12-lead ECG is per-
formed by EMS which clearly demonstrates the acute infarc-
tion. He is referred to a receiving hospital capable of primary
PCI, the cath team is notiﬁed, and the lab is activated. The
pre-hospital ECG and early activation of the lab are able
to omit some of the delays and he is taken the lab emergent-
ly. At the time of the intervention, however, in a rush to
achieve D2B less than 90 min, he undergoes direct stenting.
Although he initially does well, on hospital day two he has
recurrent chest pain with re-elevation of the ST segments
and returns to the lab demonstrating acute stent thrombosis.
Intravascular ultrasound demonstrates an undersized stent
with incomplete stent apposition and he undergoes repeat
angioplasty successfully. He is eventually discharged home
on hospital day eight.
This time, although he had an early presentation, the initial
hospital course was fast and efﬁcient, and the initial procedure
was deemed successful, his course was complicated by sub-
acute stent thrombosis secondary to malapposition of the
stent. Indeed countless different scenarios and variations can
be envisioned, but the ultimate goal remains to achieve proce-
dure success with short door-to-balloon times.
The CVL procedure time also can be separated into two
critical components: the ‘‘prep time’’ and the cath time. Both
times need individual attention. The ‘‘prep’’ time can be made
fairly standard and mock drills can be helpful. Throughout the
course of the SINCERE database, we challenged ourselves and
made efforts to improve both markers, the D2B time and the
procedure time, at all ﬁve hospitals. The improvement in mean
procedure times demonstrates a clear learning curve with
improvement in efﬁciency. It also may indicate a resolution
on the part of the operator and the team as a whole to achieve
these goals. In order to deem a procedure completely success-
ful the PPCI must achieve clinical resolution of symptoms and
electrocardiographic and angiographic markers of reperfusion.
In our experience this came to mean: relief of chest pain; ST
segment resolution; TIMI 3 ﬂow and Myocardial Perfusion
Grade 3.8. Procedural characteristics for SINCERE database
As the SINCERE experience progressed, the abundance of
thrombus in the culprit STEMI lesions became evident. Rec-
ognizing the central role of thrombus in the pathophysiology
of AMI, an effective anticoagulation and antiplatelet strategy
is essential. Aspirin therapy is ﬁrst line therapy for AMI
(Antman et al., 2004), and clopidogrel has also been shown
to have a beneﬁcial role in STEMI whether or not the patient
has PCI (Sabatine et al., 2005; Chen et al., 2005). GIIb/IIIa
use, in the setting of STEMI, most of the data until recently
has been with the use of upstream abciximab. Therefore with-
in the SINCERE database, our preference was for using
abciximab in the majority of patients in which we used a
GIIb/IIIa inhibitor. Again, despite lack of deﬁnitive clinical
data, our anticoagulant of choice was bivalirudin. We were
able to achieve good results with this agent with a low rate
of major bleed and/or stent thrombosis. Major bleed and
the need for blood transfusion is a predictor of worse long-
term outcome (Kinnaird et al., 2003). Therefore decreasing
the rate of major bleeds and need for blood transfusions im-
parts a signiﬁcant clinical beneﬁt. Stent thrombosis is a major
concern and we did experience two cases of sub-acute stent
thrombosis requiring a repeat intervention. Although we can-
not compare these rates to unfractionated heparin within our
study, the rate is less than in the recent HORIZONS trial
which demonstrated a rate of stent thrombosis of 2.5% with
bivalirudin as compared to 1.9% with the combination of
heparin and a GIIb/IIIa. In the presence of residual throm-
bus or other high-risk angiographic features, therefore a
bail-out strategy with a GIIb/IIIa agent may be beneﬁcial.
Another theoretical concern with the use of bivalirudin is that
there is no reversal agent. There were no cases of coronary
perforation with attempted PCI. Bivalirudin exhibits linear
pharmacokinetics and given its short half-life (25 min), dis-
continuation of the drug may be sufﬁcient in most cases as
coagulation parameters return to normal within 1–2 h. In ret-
rospective reviews of cases with coronary perforations tradi-
tionally on heparin therapy and or GIIb/IIIa, more than
three-quarter of cases are managed without necessitating
reversal of the anticoagulation (Stone Gregg, 2007). If emer-
gent surgery is required, by the time of surgery the effect
should be fully reversed.
Review of the procedural characteristics within the SIN-
CERE database demonstrated a few interesting points:
1. All procedures were performed via a 6 French arterial
sheath.
2. 382/420 STEMI interventions were performed with hydro-
philic wires.
3. The majority of cases 89.4%, required only culprit lesion
intervention, regardless of concomitant disease.
4. An increasing proportion of patients safely underwent aspi-
ration and/or thrombectomy, and this was done:
 Based on a system of grading thrombus severity.
 Without delaying reperfusion signiﬁcantly, or adding signif-
icant amount of procedure time.
5. A brief checklist is an effective way of roughly assessing
viability of long-term clopidogrel treatment and hence
altering the decision between bare metal vs drug-eluting
stent.
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myocardial perfusion.
Although 7 or 8 French guiding catheters may provide
additional support for PCI, in the vast majority of patients this
is rarely needed. Unlike complex chronic total occlusions or
calciﬁed lesions that may require more guide catheter support,
a STEMI lesion is usually soft and friable and does not require
excessive guide catheter support. Occasionally, the guiding
catheter may need to be exchanged for an alternate shape in
order to align the catheter more coaxial with the vessel. In
our experience, even some tortuous and distal thrombotic le-
sions were easily performed with a 6 F system. As compared
to 7 or 8 F sheaths, the smaller 6 French access sheaths may
ultimately decrease the risk of bleeding and may contribute
to the low rates of bleeding witnessed in SINCERE. Other fea-
tures responsible for low bleeding may be avoidance of venous
sheaths and the use of Bivalirudin.
Hydrophilic guidewires appear to be safe and efﬁcacious in
the setting of AMI and they may facilitate rapid crossage of
thrombotic lesions and occlusions. In addition, we do not ﬁnd
any reason to use longer wires. Our clear personal favorite is
the Choice PT wire with extra support, although other wires
were used as well including the ﬂoppy wires, the Graphix wire,
and the Whisper wire. Overall, the majority of these proce-
dures were successful without needing to change the guidewire
and were performed safely without any perforations. Recog-
nizing the fact that numerous other guide wires may be equally
outstanding, we support our recommendation based upon our
personal use in the SINCERE database.
Recognizing the role of thrombus in STEMI intervention
and the critical need to ﬁrst treat it before proceeding with
stenting was addressed and when needed, aspiration atherec-
tomy and Possis Angiojet atherectomy were used in roughly
a third of procedures. The use increased as the database pro-
gressed and it reﬂects our belief in thrombus removal upon
its recognition. We also gained experience grading the throm-
bus load and calibrating our thrombectomy technique based
on its severity; milder grades could be direct stented, moderate
thrombus could be treated with aspiration catheters and
Angiojet was used in severe thrombotic lesions and in throm-
botic occlusions. We believe that the high success rates in the
SINCERE database are attributable signiﬁcantly to identifying
and focusing on the culprit lesion. In the SINCERE database
in of the procedures PCI was performed for only the ‘‘culprit
lesion’’. We ﬁnd no advantage chasing side-branches that are
not culprit or treating lesions that are severe, but not the cul-
prit. The latter can be dangerous and unnecessary and we ﬁnd
it important to emphasize the point to focus on the culprit
lesion.
We strongly feel that the crux of the decision whether to
use a Bare Metal or a Drug-Eluting Stent for STEMI inter-
ventions rests signiﬁcantly on the patient’s perceived ability
to use long-term antiplatelet agents. The predominant con-
cern with DES has been the concern over the risk of stent
thrombosis, particularly in the long-term. We have formal-
ized this concept and made it a part of the rapid evaluation
process prior to STEMI interventions. It is an intuitive check-
list with immense implications and for which we have coined
a provocative term: ‘‘The Plavix Test’’. The underlying goal
behind this checklist is to identify any particular reasons that
the patient may not be willing or able to continue long-termdual antiplatelet therapy and consequently be at an increased
risk of stent thrombosis if a DES is used. In the ﬁve institu-
tions where the STEMI interventions are performed this sim-
ple test is often administered by the CVL support staff.
Pending possible new drugs on the market, in the future,
the evaluation process may become more convoluted and in-
volve a more formal risk-stratiﬁcation. However, the underly-
ing questions and concerns will remain the same. The
SINCERE database also reinforces our belief in the use of
a coronary vasodilator for improved myocardial perfusion,
in particular the use of intracoronary nitroprusside. This is
neither a novel drug nor a novel use of the agent, but its fre-
quent use for STEMI interventions in SINCERE has clearly
demonstrated its beneﬁts in this large cohort. The various
recommendations are enumerated in the next chapter. It is
also recognized that various other agents may have similar
beneﬁts and we ﬁnd this perfectly acceptable. Our strong rec-
ommendation is to use an intracoronary agent for all their
numerous beneﬁts in all STEMI interventions.
We believe that these form ﬁve fundamental tenets of
thrombus management for STEMI interventions: Upstream
Abciximab, Bivalirudin, Hydrophilic guidewires, Aspiration
Atherectomy and Intracoronary vasodilators.
For uncomplicated patients, who have a successful short
D2B STEMI intervention early discharge is possible. The
early discharge over time is gradually being converted to very
early discharge in SINCERE, and we wonder what the
appropriate duration of stay in the hospital is after successful
STEMI interventions. We have rarely encountered problems
post STEMI interventions, but we qualify after short and
uncomplicated D2B STEMI interventions. Of course, this
group does not include patients with severe additional lesion,
or patients who presented with complications or sustained
complications during the STEMI intervention or during the
course of their hospitalization. These are the majority of
the low-risk patients that demonstrate excellent long-term
outcomes after STEMI interventions. For these patients,
there appears no reason not to evaluate for hospital discharge
even sooner than our own recommendation of 3-day hospital
stay.9. Temporal trends in care identiﬁed in SINCERE
As previously mentioned, our anticoagulation strategy for
STEMI has largely relied on bivalirudin over the past
4+ years. Whereas initially our use of upstream GIIb/IIIa
therapy was higher, our use of upstream therapy is decreasing
with provisional use of GIIb/IIIa agents as a bail-out strategy.
Certain scenarios where bail out therapy with GIIb/IIIa inhib-
itor may be beneﬁcial include: cases of threatened side branch
closure, incomplete reperfusion such as no-reﬂow, and/or evi-
dence of large residual thrombus load and/or distal emboliza-
tion. This again mirrors the results of the recently presented
HORIZONS trial (Stone Gregg, 2007). In addition, we have
noted, that as the SINCERE database has progressed, there
has been a steady decrease in our use of DES. For the ﬁrst
100 procedures, the use of DES was 86%. At present, for the
entire cohort of 420 procedures, the overall rate of DES is low-
er. The data from SINCERE is interesting and it may reveal
larger patterns of use and may be representative of national
or global trends.
Optimizing door-to-balloon times for STEMI interventions 24110. Conclusions from the SINCERE experience
Despite distinct clinical differences, between patients with
STEMI in terms of their clinical presentation, comorbidities,
and angiography ﬁndings, commonalities exist which allow
for the development of standardized management strategies.
Throughout the course of the database, we have further reﬁned
our standardized techniques for STEMI interventions. Stream-
lining operator techniques are intended to improve outcomes
by reducing both procedure times and D2B times. Clearly,
for many patients, individual variations in management may
be beneﬁcial and/or required. However, by approaching each
patient and situation in a systematic method, it is possible
for one to maximize efﬁciency and improve overall success.
An important caveat in all the rush and fervor to attain ideal
D2B and have high procedural success rates is not to let any
metric interfere with good patient care. Optimal patient care
must remain paramount. If the outcome is not good, does an
ideal D2B time matter? Ultimately short D2B times must
accompany, but not replace, excellent acute and long-term
STEMI outcomes.11. Limitations of study
Being a single individual registry imposes clear limitations to
the trial, in particular, as the interventional cardiologist is a
highly experienced operator (>20 years of interventional prac-
tice, >400 PCI/year and >10,000 life-time PCI procedures).
Can these results be replicated by less experienced operators?
Yet, the experience of this operator demonstrates how the
STEMI procedure and the STEMI process can become a rea-
sonably standardized procedure that can be performed at com-
munity hospitals with excellent clinical outcomes. A second
limitation was incomplete quantiﬁcation of thrombus grade
in the earlier part of the SINCERE database. The critical
importance of thrombus management has been emphasized
in the manuscript, and it is now routine practice to quantify
thrombus grade prior to using aspiration or mechanical throm-
bectomy to treat the STEMI lesion.References
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